RIDGEFIELD, CT – August 27, 2020 – Boehringer Ingelheim announced today that Jean-Michel Boers, U.S. Country Managing Director, President and CEO, has been appointed to the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA represents the United States’ leading biopharmaceutical research companies. The announcement follows the recent appointment in July of Mr. Boers as Boehringer Ingelheim’s U.S. Country Managing Director, President & CEO.
“The U.S. market plays a pivotal role when it comes to pharmaceutical innovation for better patient outcomes. The appointment of Jean-Michel is important for Boehringer Ingelheim in continuing our efforts to help advance current healthcare and industry policy framework in the U.S.,” said Carinne Brouillon, Member of the Board of Managing Directors at Boehringer Ingelheim with responsibility for the Human Pharma Business Unit.
“PhRMA’s board members are critical to driving forward policies that bolster innovation and improve patient access and affordability,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “I look forward to working with Jean-Michel in his new role as he takes the helm at Boehringer Ingelheim in the U.S. and continues the company’s legacy of leadership in the biopharmaceutical industry.”
Prior to taking over as CEO for Boehringer Ingelheim in the U.S., Jean-Michel served as President of Boehringer Ingelheim Pharmaceuticals, Inc., where he was responsible for the U.S. commercial and medical organization. Mr. Boers joined Boehringer Ingelheim in 1998, and advanced through various leadership roles in corporate and operating units. He earned a master’s degree in social and economic history from the University of Nijmegen (Netherlands) and an MBA from the University of Texas (U.S.).
“The biopharmaceutical industry has an incredible impact on human health and society as a whole, perhaps now more than ever before,” said Mr. Boers. “Today’s rapid pace of innovation in healthcare is driven by passionate, talented and committed men and women who are dedicated to help save lives. As a member of PhRMA’s Board of Directors, I will advocate for solutions to ensure continued scientific advancements and access to therapies for patients.”
Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
Media Contacts for the U.S.:
Boehringer Ingelheim Pharmaceuticals, Inc.
Michele Baer
Ridgefield, CT 06877
Phone: +1 917-584-9293
Email: press@boehringer-ingelheim.com